Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Open Biopsy in Patients With Acute Progressive Neurologic Decline and Absence of Mass Lesion
Neurol 75:419-424, Schuette,A.J., et al, 2010
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Role of Brain Biopsy in the Management of Focal Brain Lesions in HIV-Infected Patients
Neurol 54:993-997, Antinori,A.,et al, 2000
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Disclosure of APOE Genotype for Risk of Alzheimers Disease
NEJM 361:245-254,298, Green,R.C.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava
Ann Int Med 136:42-53, Ernst,E., 2002